Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia

A. Gabrielli, Z. X. Zhang, G. Cherubini, M. Candela, S. Savoldi, A. Manzin, M. Clementi, A. Amoroso, M. Sallberg

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In this study we have evaluated the prevalence of antibodies against core region peptides (residues 1 28, 21-38 and 51-68), the envelope 1, the non-structural (NS) 4 and 5 proteins of hepatitis C virus (HCV) in sera from 65 chronically HCV-infected patients, 47 with mixed cryoglobulinaemia (MC+) and 18 without (MC-). The major binding sites were located within the core region. Regions 1 28 and 51 68 were recognized by a similar proportion of MC+ and MC- patients, while peptide 21-38 was less frequently detected by samples from MC+ patients (65.5% versus 100%; P = 0.011). The patterns of the reactions showed a minimum of three binding sites: one, located within region 51-68, was shared by both groups, a second determinant was identified at residues 1 21 for MC+ patients and at residues 28 38 for MC- patients; a third, not exactly localized, lay between residues 1 and 38. Recognition of NS5 peptides was not significantly different between MC+ and MC- patients, but while the former mostly reacted either with peptide 1 (residues 2294- 2309) (five of 15 sera)or with peptide 2 (residues 2304-2319) (nine of 15 sera), the latter group showed a more scattered reaction. Antibodies to HCV peptides prevalently belonged to IgG1 subclass. However, whereas IgG1 antibodies against peptide 21-38 and peptide 1 of NS5 were more frequently found in MC- rather than in MC+ patients (100% versus 63.8%, P = 0.003, and 22.2% versus 4.2%, P = 0.025, respectively), IgG3 antibodies against region 1-28 were more frequent in MC+ patients (53.19% versus 16.6%, P = 0.0078). Overall, the data suggest that a differential humoral immune response to HCV antigens occurs in patients with and without cryoglobulinaemia.

Original languageEnglish
Pages (from-to)59-64
Number of pages6
JournalClinical and Experimental Immunology
Volume105
Issue number1
Publication statusPublished - 1996

Fingerprint

Cryoglobulinemia
Humoral Immunity
Hepacivirus
Peptides
Immunoglobulin G
Antibodies
Hepatitis C Antigens
Serum
Binding Sites
Hepatitis C Antibodies
Protein C

Keywords

  • cryoglobulinaemia
  • hepatitis C virus
  • immunity
  • infection

ASJC Scopus subject areas

  • Immunology

Cite this

Gabrielli, A., Zhang, Z. X., Cherubini, G., Candela, M., Savoldi, S., Manzin, A., ... Sallberg, M. (1996). Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. Clinical and Experimental Immunology, 105(1), 59-64.

Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. / Gabrielli, A.; Zhang, Z. X.; Cherubini, G.; Candela, M.; Savoldi, S.; Manzin, A.; Clementi, M.; Amoroso, A.; Sallberg, M.

In: Clinical and Experimental Immunology, Vol. 105, No. 1, 1996, p. 59-64.

Research output: Contribution to journalArticle

Gabrielli, A, Zhang, ZX, Cherubini, G, Candela, M, Savoldi, S, Manzin, A, Clementi, M, Amoroso, A & Sallberg, M 1996, 'Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia', Clinical and Experimental Immunology, vol. 105, no. 1, pp. 59-64.
Gabrielli, A. ; Zhang, Z. X. ; Cherubini, G. ; Candela, M. ; Savoldi, S. ; Manzin, A. ; Clementi, M. ; Amoroso, A. ; Sallberg, M. / Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia. In: Clinical and Experimental Immunology. 1996 ; Vol. 105, No. 1. pp. 59-64.
@article{cf9eb5ce6a654527a92fbd58818a4834,
title = "Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia",
abstract = "In this study we have evaluated the prevalence of antibodies against core region peptides (residues 1 28, 21-38 and 51-68), the envelope 1, the non-structural (NS) 4 and 5 proteins of hepatitis C virus (HCV) in sera from 65 chronically HCV-infected patients, 47 with mixed cryoglobulinaemia (MC+) and 18 without (MC-). The major binding sites were located within the core region. Regions 1 28 and 51 68 were recognized by a similar proportion of MC+ and MC- patients, while peptide 21-38 was less frequently detected by samples from MC+ patients (65.5{\%} versus 100{\%}; P = 0.011). The patterns of the reactions showed a minimum of three binding sites: one, located within region 51-68, was shared by both groups, a second determinant was identified at residues 1 21 for MC+ patients and at residues 28 38 for MC- patients; a third, not exactly localized, lay between residues 1 and 38. Recognition of NS5 peptides was not significantly different between MC+ and MC- patients, but while the former mostly reacted either with peptide 1 (residues 2294- 2309) (five of 15 sera)or with peptide 2 (residues 2304-2319) (nine of 15 sera), the latter group showed a more scattered reaction. Antibodies to HCV peptides prevalently belonged to IgG1 subclass. However, whereas IgG1 antibodies against peptide 21-38 and peptide 1 of NS5 were more frequently found in MC- rather than in MC+ patients (100{\%} versus 63.8{\%}, P = 0.003, and 22.2{\%} versus 4.2{\%}, P = 0.025, respectively), IgG3 antibodies against region 1-28 were more frequent in MC+ patients (53.19{\%} versus 16.6{\%}, P = 0.0078). Overall, the data suggest that a differential humoral immune response to HCV antigens occurs in patients with and without cryoglobulinaemia.",
keywords = "cryoglobulinaemia, hepatitis C virus, immunity, infection",
author = "A. Gabrielli and Zhang, {Z. X.} and G. Cherubini and M. Candela and S. Savoldi and A. Manzin and M. Clementi and A. Amoroso and M. Sallberg",
year = "1996",
language = "English",
volume = "105",
pages = "59--64",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia

AU - Gabrielli, A.

AU - Zhang, Z. X.

AU - Cherubini, G.

AU - Candela, M.

AU - Savoldi, S.

AU - Manzin, A.

AU - Clementi, M.

AU - Amoroso, A.

AU - Sallberg, M.

PY - 1996

Y1 - 1996

N2 - In this study we have evaluated the prevalence of antibodies against core region peptides (residues 1 28, 21-38 and 51-68), the envelope 1, the non-structural (NS) 4 and 5 proteins of hepatitis C virus (HCV) in sera from 65 chronically HCV-infected patients, 47 with mixed cryoglobulinaemia (MC+) and 18 without (MC-). The major binding sites were located within the core region. Regions 1 28 and 51 68 were recognized by a similar proportion of MC+ and MC- patients, while peptide 21-38 was less frequently detected by samples from MC+ patients (65.5% versus 100%; P = 0.011). The patterns of the reactions showed a minimum of three binding sites: one, located within region 51-68, was shared by both groups, a second determinant was identified at residues 1 21 for MC+ patients and at residues 28 38 for MC- patients; a third, not exactly localized, lay between residues 1 and 38. Recognition of NS5 peptides was not significantly different between MC+ and MC- patients, but while the former mostly reacted either with peptide 1 (residues 2294- 2309) (five of 15 sera)or with peptide 2 (residues 2304-2319) (nine of 15 sera), the latter group showed a more scattered reaction. Antibodies to HCV peptides prevalently belonged to IgG1 subclass. However, whereas IgG1 antibodies against peptide 21-38 and peptide 1 of NS5 were more frequently found in MC- rather than in MC+ patients (100% versus 63.8%, P = 0.003, and 22.2% versus 4.2%, P = 0.025, respectively), IgG3 antibodies against region 1-28 were more frequent in MC+ patients (53.19% versus 16.6%, P = 0.0078). Overall, the data suggest that a differential humoral immune response to HCV antigens occurs in patients with and without cryoglobulinaemia.

AB - In this study we have evaluated the prevalence of antibodies against core region peptides (residues 1 28, 21-38 and 51-68), the envelope 1, the non-structural (NS) 4 and 5 proteins of hepatitis C virus (HCV) in sera from 65 chronically HCV-infected patients, 47 with mixed cryoglobulinaemia (MC+) and 18 without (MC-). The major binding sites were located within the core region. Regions 1 28 and 51 68 were recognized by a similar proportion of MC+ and MC- patients, while peptide 21-38 was less frequently detected by samples from MC+ patients (65.5% versus 100%; P = 0.011). The patterns of the reactions showed a minimum of three binding sites: one, located within region 51-68, was shared by both groups, a second determinant was identified at residues 1 21 for MC+ patients and at residues 28 38 for MC- patients; a third, not exactly localized, lay between residues 1 and 38. Recognition of NS5 peptides was not significantly different between MC+ and MC- patients, but while the former mostly reacted either with peptide 1 (residues 2294- 2309) (five of 15 sera)or with peptide 2 (residues 2304-2319) (nine of 15 sera), the latter group showed a more scattered reaction. Antibodies to HCV peptides prevalently belonged to IgG1 subclass. However, whereas IgG1 antibodies against peptide 21-38 and peptide 1 of NS5 were more frequently found in MC- rather than in MC+ patients (100% versus 63.8%, P = 0.003, and 22.2% versus 4.2%, P = 0.025, respectively), IgG3 antibodies against region 1-28 were more frequent in MC+ patients (53.19% versus 16.6%, P = 0.0078). Overall, the data suggest that a differential humoral immune response to HCV antigens occurs in patients with and without cryoglobulinaemia.

KW - cryoglobulinaemia

KW - hepatitis C virus

KW - immunity

KW - infection

UR - http://www.scopus.com/inward/record.url?scp=0030016033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030016033&partnerID=8YFLogxK

M3 - Article

C2 - 8697636

AN - SCOPUS:0030016033

VL - 105

SP - 59

EP - 64

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -